Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib vs Enzalutamide or Abiraterone Acetate in Chinese Men With mCRPC and BRCA1/2 Mutations (PROfound-CN)
NCT05457257Phase 4Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2022
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of olaparib in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by AstraZeneca. Primary endpoint: Radiological Progression-free Survival. Started Jul 2022; status: active, not recruiting.
02
Drugs
olaparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05457257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05457257.